Pharma Focus America

Myriad Genetics and GSK Team Up to Broaden Access to HRD Testing in Nine Countries

Wednesday, June 12, 2024

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has announced a partnership with GSK to improve access to homologous recombination deficiency (HRD) diagnostic testing for patients with high-grade serous ovarian cancer (HGSOC). This initiative will use Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests, collectively known as Myriad’s MyChoice Tests, and will be available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and the United Arab Emirates.

HRD testing is an essential predictive and prognostic tool for ovarian cancer patients. Myriad's MyChoice Tests evaluate HRD status, allowing healthcare providers to order the tests through local pathology labs, with the samples analyzed by Myriad Genetics.

This collaboration highlights both companies' dedication to improving care for patients with advanced ovarian cancer by enhancing access to genetic testing, addressing a critical need for patients who might otherwise not have access to such testing.

“Our collaboration with GSK is an important step forward in providing crucial genetic insights that can help clinicians make more personalized treatment decisions for ovarian cancer,” said Patrick Burke, PhD, EVP of Strategy and Innovation at Myriad Genetics. “In our efforts to advance healthcare equity, Myriad is committed to expanding the reach of our diagnostic solutions, such as Myriad’s MyChoice Tests, to support more personalized patient care based on their genetic profiles.”

Myriad’s MyChoice® test is a comprehensive tool for determining HRD status through the assessment of genomic alterations in genes like BRCA1 and BRCA2, and the Genomic Instability Score (GIS) using Myriad’s proprietary algorithm. It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatments involving targeted therapies.

 

Source: globenewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024